Important safety information

Clinical use:

Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.

• Safety and efficacy in geriatric patients (≥65 years) has not been established
• No clinical trial efficacy and safety experience with CRYSVITA in patients <1 year of age

Contraindications:

CRYSVITA is contraindicated:

• In use with oral phosphate and/or active vitamin D analogues (calcitriol or alfacalcidol)
• If serum phosphorus is within or above the normal range for age
• In patients with severe renal impairment or end-stage renal disease

Relevant warnings and precautions:

• Hyperphosphatemia and risk of ectopic mineralization, most commonly nephrocalcinosis
• Injection site reactions, especially in pediatric patients
• Vitamin D decrease
• Driving and operating machinery
• Hypersensitivity reactions such as rash, urticaria, and facial swelling
• Fertility
• Pregnant women
• Breastfeeding

For more information:

Please consult the CRYSVITA Product Monograph for important information relating to adverse reactions and drug interactions that has not been discussed in this piece. The Product Monograph is also available by calling us at 1-866-590-9508.